Back to Newsroom

Arena Pharmaceuticals Announces Filing for Marketing Authorization of BELVIQ(R) (lorcaserin HCl) in Brazil

— Eisai’s Filing for Approval of BELVIQ as a Treatment for Chronic Weight Management Triggers $500,000 Milestone Payment to Arena —

SAN DIEGO, Feb. 12, 2014 — Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that Eisai Laboratorios Ltda., a subsidiary of Eisai Inc., has filed for marketing authorization of BELVIQ® as a treatment for chronic weight management with the Brazilian Health Surveillance Agency (Anvisa). In connection with the filing, Arena will receive a milestone payment of $500,000 from Eisai.